GlassScriptPhysician profile
Tran H Ly
NPI 1053520296
$3,775.77
in general payments reported to CMS, 2019-2025
18 companies · $770 in 2025
The $770 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $86.96 · 2021: $12.46 · 2022: $735 · 2023: $722 · 2024: $1,074 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,002.03 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $837.65 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $529.38 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $284.18 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $253.17 | 2022-2025 | |
| Genentech USA, INC. | $143.38 | 2024 | Xolair |
| Blueprint Medicines Corporation | $125.69 | 2023-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $118.27 | 2021-2024 | Takhzyro, Hyqvia |
| Grifols USA, LLC | $110.67 | 2023-2025 | Xembify, Gamunex-C |
| Amgen INC. | $93.35 | 2022-2025 | Tezspire |
| Optinose US, INC. | $61.91 | 2022-2024 | |
| Alk-Abello, INC | $59.69 | 2019-2022 | |
| Octapharma USA, INC. | $47.30 | 2023 | Cutaquig |
| Fortovia Therapeutics, INC. | $29.79 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $24.12 | 2025 | Neffy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $23.15 | 2022 | |
| Merck Sharp & Dohme LLC | $18.00 | 2023 | |
| Pfizer INC. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tran Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.